Olanzapine

證據等級: L5

預測適應症: 3 個

Olanzapine: From Antipsychotic Therapy to Anxiety-Spectrum Indications (Agoraphobia / Dysthymic Disorder)

One-Sentence Summary

Olanzapine is a well-established atypical antipsychotic; however, this evidence pack contains no Finland-specific regulatory or original-indication data (the drug is not marketed in Finland). Among three TxGNN-predicted indications, the top-ranked candidate (benign paroxysmal torticollis of infancy) is not mechanistically or clinically plausible, while agoraphobia and dysthymic disorder are supported by small open-label trials, case reports, and reviews — no completed RCTs — for a total of 12 publications and 0 registered clinical trials across all three candidates.

Predicted Indications Overview

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Benign paroxysmal torticollis of infancy	99.54%	L5	Hold — no supporting studies; mechanistically implausible (infant population, non-monoaminergic pathophysiology)
2	Agoraphobia	99.47%	L3	Research Question
3	Dysthymic disorder	99.28%	L3	Research Question

Rank 1 is excluded from the sections below because it has zero clinical trial or literature evidence and the model's own mechanistic rationale argues against pursuing it (antipsychotic use in infants carries significant EPS/metabolic/sedation risk with no disease-mechanism rationale). The remainder of this report focuses on agoraphobia as the primary candidate, with dysthymic disorder as a secondary candidate.

Quick Overview

Item	Content
Original Indication	Not available — Finland market data shows the drug as unmarketed, with no license records in this evidence pack
Predicted New Indication	Agoraphobia (primary); Dysthymic Disorder (secondary)
TxGNN Prediction Score	99.47% (agoraphobia)
Evidence Level	L3 (observational/open-label/review level; no completed RCTs)
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, olanzapine is a second-generation antipsychotic with combined D2 and 5-HT2A receptor antagonism, and it is already approved elsewhere (outside Finland, per available records) in combination with fluoxetine for treatment-resistant depression — indicating precedent for its use in mood/anxiety-adjacent indications as an augmentation agent.

Agoraphobia commonly co-occurs with panic disorder, and its pathophysiology involves amygdala hyperactivation and dysregulated serotonergic/noradrenergic signaling. Olanzapine's 5-HT2A antagonism and sedative properties provide a plausible augmentation mechanism for SSRI/SNRI-refractory panic disorder with agoraphobia, but the supporting evidence comes from a single 12-week open-label trial (n=31) plus case reports — not indication-specific randomized data.

Dysthymic disorder (persistent low-grade depression) similarly involves monoamine (5-HT/NE/DA) dysregulation. The augmentation rationale mirrors olanzapine's approved role alongside fluoxetine in treatment-resistant depression. However, direct evidence is limited to one small open-label study in a borderline personality disorder population with comorbid dysthymia; the remaining literature on second-generation antipsychotics for dysthymia is largely indirect (reviews of the drug class, or studies of other agents such as amisulpride/sulpiride rather than olanzapine itself).

Clinical Trial Evidence

Currently no related clinical trials registered for agoraphobia or dysthymic disorder (ClinicalTrials.gov and ICTRP both returned zero results for both indications).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
16415705	2006	Open-label trial	J Clin Psychopharmacol	12-week fixed-dose open-label study (n=31): low-dose olanzapine (5 mg/d) augmentation of SSRI in treatment-resistant panic disorder with/without agoraphobia
10578457	1999	Open-label trial	Biological Psychiatry	Open-label olanzapine trial in borderline personality disorder with comorbid dysthymia; objective rating scales used
26635099	2016	Review	Expert Opinion on Pharmacotherapy	Systematic review of treatment-resistant panic disorder; ~1/3 of patients have persistent symptoms after standard treatment
40946318	2025	Review	Psychotherapy and Psychosomatics	Integrative review of pharmacological, psychotherapeutic, and neurostimulatory options for treatment-resistant anxiety disorders
21154393	2010	Review (Cochrane)	Cochrane Database of Systematic Reviews	Second-generation antipsychotics (including olanzapine) as augmentation for major depressive disorder and dysthymia
22938165	2012	Review	Bipolar Disorders	Evidence-based options for treatment-resistant bipolar disorder, including comorbid anxiety/dysthymic presentations
25012437	2014	Cohort	Journal of Affective Disorders	Impact of comorbid anxiety disorders (including agoraphobia) and OCD on 24-month outcomes of bipolar I disorder
10739446	2000	Case report	American Journal of Psychiatry	Early case report describing olanzapine use in panic attacks
15470803	2004	Case report	Pharmacopsychiatry	Case report: remission of chronic treatment-refractory panic disorder with olanzapine + paroxetine combination
17099612	2006	Case report	Psychiatria Danubina	Case report of CBT treatment for panic disorder with agoraphobia comorbid with psychosis

Two additional dysthymia-related papers (PMID 11920152, 34727399) were excluded from this table because they concern other agents (substituted benzamides/amisulpride), not olanzapine directly.

Finland Market Information

Olanzapine is not currently marketed in Finland, and no authorization records are available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information. Note: TFDA package insert warnings/contraindications and drug interaction data could not be retrieved for this evaluation (a Blocking-severity data gap), which prevents a full initial safety assessment.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for agoraphobia and dysthymic disorder is limited to small open-label studies, case reports, and indirect class-level reviews (L3), with no completed RCTs in either indication, and the top TxGNN-ranked prediction (infantile torticollis) lacks any supporting studies or mechanistic plausibility. Critically, TFDA package insert warnings/contraindications are unavailable (Blocking gap), which by itself precludes an initial safety assessment regardless of efficacy evidence strength.

To proceed, the following is needed:

TFDA/manufacturer package insert (warnings, contraindications, DDI) to complete initial safety screening
Confirmed original indication and MOA data from DrugBank or equivalent source
A prospective or randomized study specifically in agoraphobia or dysthymic disorder populations, rather than relying on panic-disorder-comorbid or borderline-personality-disorder cohorts
Reassessment of the torticollis candidate as low priority given absent evidence and unfavorable risk profile in an infant population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.